PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL